Background: Germline BRCA2 mutations are associated with poorer outcome prostate cancer (PCa) compared with sporadic tumours but this association remains to be characterised. In this study, we aim to assess if there is a signature set of copy number alterations (CNA) that could aid to the identification of BRCA2-mutated tumours and would assist us to understand their aggressive clinical behaviour.
High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers ). A hundred and sixteen regions had a significantly different distribution with both false discovery rate (FDR) and P value <0.01, including CNA in the genomic region containing c-MYC that was present in 89% B2T versus 12.5% NCT (P = 3 × 10 −4 ). Loss of heterozygosity (LOH) at the BRCA2 locus was observed in 67% of B2T.
Elevated CNA are already present in 50% of the morphologically normal prostate tissue from BRCA2 carriers.
Conclusion:
The relative high amount of CNAs in morphologically normal prostate tissue of BRCA2 carriers implies a field effect and together with the observed LOH could be used as a marker of PCa risk in these men. Several features previously associated with poor PCa outcome have been found to be significantly more common in BRCA2-mutated PCa than in sporadic tumours and may help to explain their adverse prognosis and be of relevance for targeted therapies. Key words: prostate cancer, germline, BRCA2, CNV, c-MYC, LOH introduction Prostate cancer (PCa) is a major health burden worldwide and although the majority of patients can be successfully treated, some tumours develop aggressively, resulting in metastasis and death from PCa. This clinical heterogeneity is echoed by the molecular heterogeneity seen within prostate tumours. One group of patients at high risk of lethal forms of PCa is men with germline mutations in the BRCA2 gene. BRCA2 germline mutations confer the highest risk of PCa known to date (8.6-fold in men ≤65 years) [1] , and are also associated with a more aggressive phenotype and poorer prognosis [2] [3] [4] [5] [6] . Following conventional treatment of localised PCa, BRCA mutation carriers develop metastasis earlier and more often than noncarriers [7] . Furthermore, BRCA2 germline mutations have been reported to be an independent prognostic factor for metastasisfree survival and PCa-specific survival [3] . The molecular characterisation of BRCA2-mutated tumours may be essential in tailoring treatment of mutation carriers, but it may also be of great importance for the management of some sporadic PCa cases with similar clinical characteristics and aggressive behaviour. Germline BRCA2 mutation in sporadic PCa is a rare event (1.2%) [1] , but recent studies have shown that up to 13% of sporadic tumours harbour somatic BRCA2 homologous deletions or point mutations [8, 9] . Studies in breast and ovarian cancer have identified sporadic cancers with molecular and clinical characteristics similar to BRCA-related tumours [10] [11] [12] . The phenotype that some sporadic tumours share with familial-BRCA cancer has been termed BRCAness [12] and it is yet to be elucidated in PCa. Defining all these groups of tumours may have clinical implications, not only because BRCAdeficient PCa tumours have worse outcomes than homologous recombination (HR)-proficient tumours when conventionally treated [7] but also because HR-deficient tumours have been shown to be highly sensitive to alkylating agents and to poly ADP-ribose polymerase (PARP) inhibitors [13] .
In this study, genome-wide high-resolution array comparative genomic hybridisation (aCGH) has been used to identify the genetic aberrations present in tumours with BRCA2 germline mutations and the frequency of those genomic events compared with tumours without such mutations. We aimed to assess both the number of aberrations present in these tissues when compared with non-carrier tumour tissue and ascertain if there is a signature set of CNAs that can classify tissues within these classes and that could explain the aggressive clinical behaviour of BRCA2-mutated tumours.
materials and methods patients
Formalin-fixed paraffin-embedded (FFPE) PCa samples from 20 BRCA2 germline mutation carriers and 40 BRCA2 non-carriers enrolled in the UK Genetics Prostate Cancer Study (UKGPCS), the Epidemiological Study of Familial Breast Cancer (EMBRACE) and the Identification of Men with a Genetic Predisposition to Prostate Cancer: Targeted Screening in BRCA1/2 Mutation Carriers and Controls (IMPACT) study were collected. All noncarrier cases (sporadic tumours) had previously been screened and found not to carry any BRCA2 mutations [1] . Prostate samples were obtained from prostatectomies or diagnostic biopsies of primary tumours with the participants' signed consent. None of the patients had received any treatment of PCa, including androgen deprivation therapy, at the time of sample collection.
DNA extraction
An expert pathologist identified areas of >75% tumour in haematoxylineosin slides for macro-dissection with a scalpel. Necrotic areas were excluded. Benign prostate tissue was also obtained for all cases, at least 5 mm away from PCa. DNA was extracted from the tissue scrapings using the QIAmp DNA FFPE Tissue kit (Qiagen, Valencia, CA) as per the manufacturer's protocol. DNA was quantified using a Nanodrop spectrophotometer. DNA quality was assessed by the 260:280 and 260:230 ratios and its integrity by agarose gel ethidium bromide visualisation. Samples whose 260:280 and 260:230 ratios were <1.8, were excluded.
preparation and hybridisation of samples
Labelling of FFPE tumour and reference DNA was carried out using the Genomic DNA ULS Labeling kit (Agilent) according to the manufacturer's instructions. As reference, a pool of 37 samples of DNA obtained from noncarriers' prostate benign tissue was used. Three hundred nanograms of this pool was amplified to be used as reference for the amplified samples.
DNA samples were labelled with Cyanine 3 (Cy3) (green) and the reference DNA with Cyanine 5 (Cy5) (red). Labelling, array hybridisation to SurePrint G3 Human CGH Microarray Kit, 2× 400 K (Agilent) and scanning were carried out at the Oxford Gene Technology service facility according to the Agilent Oligonucleotide Array-based CGH for Genomic DNA Analysis protocol (v3.1).
data analysis
Limma software [14] was used for processing text files generated by Agilent feature data extraction, including subtraction of background intensity data for background correction, within-array normalisation using the loess method, across array normalisation using the quantile method and calculation of the log 2 ratio of the Cy3-labeled test sample versus Cy-5 reference sample. Control probes were removed, and anomalies (outlying probes for
original articles Annals of Oncology pixel noise and background pixel noise) that had been flagged by the Agilent feature extraction software were filtered out within R [15] . Replicate probe intensities were averaged (mean) and missing probes were imputed where >10% of sample probes were missing using snapCGH impute Missing Values function [16] . After processing, 410 740 of 420 298 probe log 2 ratios were available for analysis (97.7%). Segmentation of the data was carried out with the circular binary segmentation algorithm using the CGHcall norm. cghdata function [17, 18] . Tumour cell proportion in samples was corrected for using the CGHcall cellularity correction function with all tumour samples said to have 75% tumour cells, as per extraction criteria for this experiment. Segmented log 2 ratios were used to classify CNAs as losses, normal or gains using the CGHcall function. Called data were further processed using CGHregions [19] which eliminated regions where many samples had a large overlap in consecutive clones of unchanged state, thus reducing the dimensionality of the data (regioning). Association testing between the classes of tumour were carried out on regioned data using CGHtest [20] using the χ 2 test with 10 000 permutations and false discovery rate (FDR) testing [21] .
results
DNA was extracted from 20 BRCA2 germline mutation carrier tumour (B2T), matching morphologically normal tissue (B2N), and 40 non-carrier tumour (NCT) and normal matching tissue (NCN). DNA from 37 NCN was pooled and used as the reference DNA on the array. Five B2T, four B2N, eight NCT and three NCN were excluded due to poor DNA quality. Six B2T and six NCT samples that required amplification were also excluded from the analysis as diagnostic functions in Limma demonstrated that normalisation was not sufficient to include them. Removal of amplified samples and those with poor DNA quality from the analysis resulted in a final sample set of 16 NCT, 9 B2T and 16 B2N. Matched normal prostate sample from the same patient was present for all nine BRCA2 carrier tumour samples. No significant differences were seen between carriers and non-carriers in clinico-pathological tumour features at diagnosis, except for the higher frequency of metastasis observed among BRCA2 mutation carriers (Table 1) . However, all the samples analysed corresponded to primary tumours. Across all samples, 50.4% of total CNAs observed were losses and 49.6% were classified as gains. Losses were slightly more common than gains in both NCT and B2T while gains were more common in B2N ( Table 2 ). All B2T samples exhibited a relatively high number of CNAs with a mean of 1481 aberrations (range 523-2300) (supplementary Figure S1 , available at Annals of Oncology online). Although 6 of the 16 NCT samples also fell within this range with between 750 and 996 CNAs, the remaining 10 NCT samples had 390 or fewer CNAs, with 2 samples containing fewer than 100 aberrations. B2T samples had the largest number of mean CNA (1481) compared with less than half of this for B2N samples (627) and even less (452) for NCT samples ( Table 3 ). The differences in mean aberration count between B2T and NCT were statistically significant for all copy number changes (P = 12 × 10 −3 , P = 13 × 10 −3 and P = 14 × 10 −16 for losses, gains and total aberrations, respectively) ( Table 4) . No association was found between mean aberration count with classical PCa prognostic factors such as age of onset, Gleason score, TNM stage or PSA levels at diagnosis. B2N samples were significantly different from B2T for total aberrations only (P = 44 × 10 −4 ). Further analysis of the CNA results for B2N tissue revealed that samples could be categorised into two significantly different classes, based on the total number of observed aberrations. Eight samples (50%) had fewer aberrations than the mean of B2N CNV (627.4) and were classified as B2N1 (mean 54.8 range 34-141) while another eight samples exceeded the mean (mean 1200.3 range 727-1957) and were classified as B2N2 (Table 4) . The difference in CNV between these two groups was significant (P = 9 × 10 −6 ). This range is consistent with the level of CNAs observed in the B2T samples (mean 1481, range 523-2300). The matched morphologically normal prostate tissue of four B2T fell in the B2N1 category, while the remaining five tumours had a matched B2N2 sample. The eight B2N1 samples were significantly different from B2T for all categories (P = 0.013, 0.011 and 1 × 10 −5 for losses, gains and total aberrations, respectively) ( Table 4) . On the contrary, the eight B2N2 samples did not differ significantly from B2T with regards to gains, losses or total CNA (P = 0.305). For the B2T-B2N2 pairs, the concordance in CNA between B2T and their matched B2N2 samples was 96%, 81%, 67%, 61% and 40%, respectively (supplementary Figure S2 , available at Annals of Oncology online).
comparison between groups
To determine whether there were CNA regions that differ significantly between groups, a χ 2 test statistic was calculated for each region with significance, evaluated after 10 000 permutations of group status to account for skewed distribution of the test statistic. FDRs were also calculated. Over 700 regions had a significantly different distribution between NCT and B2T with both FDR and P value <0.05 (Tables 5 and 6 ), of which, 116 had a P value and FDR <0.01 (supplementary Table S1 , available at Annals of Oncology online). Of note, 89% of B2T versus 12.5% of NCT presented gains in the 8q24.21 region, which contains c-MYC (P = 3 × 10 ). Losses in region 13q21.33 that contains BRCA2 were observed in 12.5% of NCT and 67% of B2T (P < 0.01) with FDR = 0.03. Using the same criteria (both FDR and P value <0.05), 884 regions were found to be significantly different between B2N1 and B2T, with 337 retaining significance at FDR <0.01. The greatest differences between B2N1 and B2T were observed for the regions containing c-MYC (P = 1 × 10 ) ( Figure 1 and Table 6 ). No significant differences were observed between B2T and B2N2 at both P value and FDR <0.01 ( Figure 2 ). discussion BRCA2 encodes a protein with multiple biological functions, including HR DNA repair [22, 23] . Since the identification of this gene, BRCA2 germline mutations have been associated with an increased risk of different types of cancer, including breast, ovarian and prostate [24, 25] . This predisposition has been attributed to the fact that deficiency in HR leads to the use of error-prone DNA repair mechanisms (e.g. non-homologous end-joining) and the subsequent accumulation of genomic aberrations [26] . This is the first study to investigate the genomewide CNA profile of BRCA2 mutation carriers in normal and tumour prostate tissue. We have shown that PCa tumours with germline BRCA2 mutations present with significantly more CNA than sporadic tumours, with the differences being significant for both gains and losses. We also show evidence that some of these genomic aberrations might not be random, as we have observed recurring gains and losses in the B2T samples. Our results also reveal that morphologically normal prostate tissue samples from ∼50% of the BRCA2 mutation carriers already had a substantial level of CNA compared with normal prostate tissue from non-carriers.
CNA is a common genetic change seen in PCa, including somatic mutations, small deletions and insertions and inter and intra-chromosomal rearrangements that often occur in an interdependent mode [27] . Mutations are less common in PCa than in other solid tumours, but in contrast, CNV and genomic rearrangements are significantly more common in prostate than in other cancer types. Losses have been reported to be more frequent than gains, accounting for up to 80% of the observed alterations in PCa [28] [29] [30] . According to the currently published genomic data [31] the deletion of chromosome 8p (8p23.3-p11.21, which contains the prostate-specific tumour suppressor NKX3-1) is the most recurrent somatic CNA, present in 62% of PCa. The second most frequent deletion (53%) is 13q13.1-q31.1 with a minimal region of deletion at 13q14.2 (RB1) and a original articles Annals of Oncology secondary peak at 13q21.33 (BRCA2). Chromosome 8q gain, including cytoband 8q24.21 that contains the c-MYC oncogene, was the most frequent gain observed in the 33% of cases included in the meta-analysis (in the range of 8.7%-52.5%). Additional gains are less common but include regions at 16p, the entire chromosome 7, 3q and 20p. Similar frequencies of gains and losses have been observed in our series (supplementary Tables S1 and S2 , available at Annals of Oncology online) except for a higher incidence of BRCA2 loss (67%) and MYC gain (67%) in B2T. On average B2T have more CNA than NCT with the differences being significant for both gains and losses; however, 6 of the 16 NCT samples had a similar range of CNA level to B2T samples. It is possible that those non-carrier tumours with a higher level of CNA might harbour germline or somatic alterations in other DNA repair genes, leading to similar molecular characteristics as B2T. In fact, PCa with somatic mutations in the BRCA2 and in the MSH2 genes have been reported to accumulate more somatic mutations than non-carriers [9] , but no data have been reported as yet regarding CNA. Further investigation of high CNA as a potential indicator of a BRCAness profile is warranted. Hieronymus et al. [32] have demonstrated that CNA burden is an independent prognostic factor for PCa relapse following radical prostatectomy as well as for the . Indeed, it has previously been shown that gains of 8q and relative copy number gain of c-MYC are independently associated with poorer PCa survival. Our results are of relevance as these patients could benefit from the c-MYC inhibitors that are being developed to treat c-MYCdriven PCa.
In accordance with previous reports, [8, 9] the deletion of 13q21.33, which includes the BRCA2 gene, was observed in 12.5% of NCT in our series but was significantly more frequent (67%) in BRCA2-mutated tumours (P < 0.01, FDR <0.03). Willems et al. [33] and Edwards et al. [4] have previously reported loss of heterozygosity (LOH) in 71% and 100% of PCa from BRCA2 mutation carriers. Although it is controversial whether high-grade intra-epithelial neoplasia (HGPIN) is a precursor lesion that can lead to PCa, it is interesting to note that in a cohort of 10 BRCA2 mutation carriers, Willems-Jones et al. [34] found that no patient displayed LOH in the HGPIN foci, irrespective of whether or not the corresponding PCa displayed LOH, suggesting that HGPIN may not be a cancer precursor in these patients. In our series, BRCA2 genomic loss was not observed in any sample of the morphologically normal prostate tissue from BRCA2 mutation carriers in the B2N1 group but was already present in three samples of the B2N2 group (19%). Despite the small sample size of all these studies, they together provide evidence to support the hypothesis that the loss of the non-mutated BRCA2 allele may be one of the mechanisms underlying prostate carcinogenesis in mutation carriers. BRCA2 has the hallmarks of a tumour suppressor gene and is the likely candidate to cause or promote PCa in a substantial proportion of carriers who are diagnosed with the disease. However, not all BRCA2-mutated tumours displayed LOH and, therefore, other mechanisms such as epigenetic gene silencing or acquired somatic mutations in the BRCA2 gene may be involved.
As previously presented, the morphologically normal prostate tissue samples from BRCA2 mutation carriers could be divided in two groups (B2N1 and B2N2), based on their total aberration count. All samples considered, the lack of significance in the differences in CNA between B2T and B2N2, could lead to the conclusion that B2N2 samples were contaminated with tumour cells, although all tissue blocks were evaluated and marked up by the same experienced pathologist and normal prostate tissue was obtained at least 5 mm away from PCa. Our results are supported by those of Yu et al. [35] who observed a field effect of tumour-like copy number profiles in benign tissue adjacent to prostate tumours. Furthermore, they found that CNA in normal adjacent tissue was predictive of poor clinical outcome so this could also help to explain the poor outcome observed in BRCA2-mutated PCa. Cooper et al. [36] have also reported early genomic changes in the morphologically normal tissue in the prostate based on whole-genome sequencing of multi-focal PCa. We hypothesise that the high level of CNA observed in class 2 B2N samples, including BRCA2 LOH, may represent early changes in PCa tumorigenesis, and the potential start of a new independent focus of disease. Although further studies are required to validate our findings, a high level of CNA and BRCA2 LOH in morphologically normal prostate tissue of mutation carriers could be a genomic marker of cancer risk more accurate for these patients than some pathological features such as HGPIN.
In conclusion, several features previously associated with poor PCa outcome have been found to be significantly more common in BRCA2 mutated than in sporadic tumours and these may help to explain the adverse outcome of these tumours. We have also identified c-MYC amplification as a potential treatment target for BRCA2 mutation carriers, in addition to alkylating agents and PARP inhibitors. However, the small sample size is the major limitation of this study and prevented us from identifying a signature set of CNAs that would define a BRCAness signature. A larger set of BRCA2 mutation carriers is needed to fully elucidate the genomic aberrations present in these tumours and their role in the natural history of BRCA2-related PCa. 
